ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: SA-PO0094

From Fibrosis to Failure: A Severe Case of Scleroderma Renal Crisis

Session Information

Category: Acute Kidney Injury

  • 102 AKI: Clinical, Outcomes, and Trials

Authors

  • Srivastava, Tanya, CHRISTUS Good Shepherd Health System, Longview, Texas, United States
  • Shakamuri, Shobha, CHRISTUS Good Shepherd Health System, Longview, Texas, United States
  • Sreeram, Varalaxmi, CHRISTUS Good Shepherd Health System, Longview, Texas, United States
  • Chiluveri, Madhu, CHRISTUS Good Shepherd Health System, Longview, Texas, United States
Introduction

Systemic sclerosis (SSc) is an autoimmune disease causing vasculopathy and fibrosis. Scleroderma renal crisis (SRC) presents with hypertension (HTN), anemia, thrombocytopenia, and rapidly progressing acute kidney injury (AKI).

Case Description

A 45-year-old Caucasian woman presented with worsening chest pain. History included heart failure, HTN, suspected connective tissue disease with recent anemia and thrombocytopenia. On exam, she had tight perioral skin, sclerodactyly, and elbow contractures. She was found to have hypertensive emergency (213/118). Labs revealed AKI with 2.55 mg/dL creatinine, BNP 2692, and proteinuria. ANA and RNA polymerase III (RP3) IgG were positive. Renal biopsy showed thrombotic microangiopathy consistent with SRC. She received ACE inhibitors, plasmapheresis for 5 days, and captopril 50 mg TID, with improved renal function.

Discussion

SRC affects 5–15% of SSc patients, typically early in diffuse cutaneous forms. Risk factors include rapid skin thickening, anti-RP3 antibodies, and corticosteroid use. Pathogenesis involves endothelial injury, RAAS activation, and malignant hypertension. ACE inhibitors remain first-line therapy. Complement inhibition with eculizumab shows variable benefit; further studies are warranted.

Light microscopy showed global glomerulosclerosis, ischemic hypoperfusion, onion-skinning of arterioles

Electron microscopy shows endothelial swelling, thin BM and no immune complex deposition.

Digital Object Identifier (DOI)